Successes and challenges in translational research

The development of targeted therapy for gastrointestinal stromal tumours

Daniel J. Renouf, Lora Wilson, Charles Blanke

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that most commonly affect the stomach or small intestine, but that can occur anywhere within the gastrointestinal tract. The annual incidence of GISTs is estimated to be 10 to 20 cases per million. Traditionally, the only effective treatment was surgical resection, and recurrences were common even with complete removal of tumor. Systemic therapy with standard cytotoxic chemotherapeutic agents was completely ineffective. A series of exciting laboratory developments led to the discovery that the small molecule tyrosine kinase inhibitor STI571 (imatinib mesylate) has significant clinical activity in GISTs, representing one of the first therapeutic uses of a targeted agent directed against a solid tumor. In this article we will describe the key steps that led to the initial clinical trials of imatinib in GISTs, and we will also discuss the process of incorporating this novel therapy into mainstream oncologic practice.

Original languageEnglish (US)
Pages (from-to)3908-3911
Number of pages4
JournalClinical Cancer Research
Volume15
Issue number12
DOIs
StatePublished - Jun 15 2009
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Translational Medical Research
Research
Neoplasms
Cytotoxins
Therapeutic Uses
Therapeutics
Protein-Tyrosine Kinases
Small Intestine
Gastrointestinal Tract
Stomach
Clinical Trials
Recurrence
Incidence
Imatinib Mesylate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Successes and challenges in translational research : The development of targeted therapy for gastrointestinal stromal tumours. / Renouf, Daniel J.; Wilson, Lora; Blanke, Charles.

In: Clinical Cancer Research, Vol. 15, No. 12, 15.06.2009, p. 3908-3911.

Research output: Contribution to journalArticle

@article{1558b95fc6d44f89bcb2bee90a5f4d4a,
title = "Successes and challenges in translational research: The development of targeted therapy for gastrointestinal stromal tumours",
abstract = "Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that most commonly affect the stomach or small intestine, but that can occur anywhere within the gastrointestinal tract. The annual incidence of GISTs is estimated to be 10 to 20 cases per million. Traditionally, the only effective treatment was surgical resection, and recurrences were common even with complete removal of tumor. Systemic therapy with standard cytotoxic chemotherapeutic agents was completely ineffective. A series of exciting laboratory developments led to the discovery that the small molecule tyrosine kinase inhibitor STI571 (imatinib mesylate) has significant clinical activity in GISTs, representing one of the first therapeutic uses of a targeted agent directed against a solid tumor. In this article we will describe the key steps that led to the initial clinical trials of imatinib in GISTs, and we will also discuss the process of incorporating this novel therapy into mainstream oncologic practice.",
author = "Renouf, {Daniel J.} and Lora Wilson and Charles Blanke",
year = "2009",
month = "6",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1622",
language = "English (US)",
volume = "15",
pages = "3908--3911",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Successes and challenges in translational research

T2 - The development of targeted therapy for gastrointestinal stromal tumours

AU - Renouf, Daniel J.

AU - Wilson, Lora

AU - Blanke, Charles

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that most commonly affect the stomach or small intestine, but that can occur anywhere within the gastrointestinal tract. The annual incidence of GISTs is estimated to be 10 to 20 cases per million. Traditionally, the only effective treatment was surgical resection, and recurrences were common even with complete removal of tumor. Systemic therapy with standard cytotoxic chemotherapeutic agents was completely ineffective. A series of exciting laboratory developments led to the discovery that the small molecule tyrosine kinase inhibitor STI571 (imatinib mesylate) has significant clinical activity in GISTs, representing one of the first therapeutic uses of a targeted agent directed against a solid tumor. In this article we will describe the key steps that led to the initial clinical trials of imatinib in GISTs, and we will also discuss the process of incorporating this novel therapy into mainstream oncologic practice.

AB - Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms that most commonly affect the stomach or small intestine, but that can occur anywhere within the gastrointestinal tract. The annual incidence of GISTs is estimated to be 10 to 20 cases per million. Traditionally, the only effective treatment was surgical resection, and recurrences were common even with complete removal of tumor. Systemic therapy with standard cytotoxic chemotherapeutic agents was completely ineffective. A series of exciting laboratory developments led to the discovery that the small molecule tyrosine kinase inhibitor STI571 (imatinib mesylate) has significant clinical activity in GISTs, representing one of the first therapeutic uses of a targeted agent directed against a solid tumor. In this article we will describe the key steps that led to the initial clinical trials of imatinib in GISTs, and we will also discuss the process of incorporating this novel therapy into mainstream oncologic practice.

UR - http://www.scopus.com/inward/record.url?scp=67449152478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449152478&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1622

DO - 10.1158/1078-0432.CCR-08-1622

M3 - Article

VL - 15

SP - 3908

EP - 3911

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -